Trevi Therapeutics Stock Working Capital
| TRVI Stock | USD 4.36 0.24 5.83% |
Trevi Therapeutics fundamentals help investors to digest information that contributes to Trevi Therapeutics' financial success or failures. It also enables traders to predict the movement of Trevi Stock. The fundamental analysis module provides a way to measure Trevi Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Trevi Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 94 M | 53.8 M | |
| Change In Working Capital | -3.5 M | -3.3 M |
Trevi | Working Capital |
Trevi Therapeutics Company Working Capital Analysis
Trevi Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Trevi Therapeutics Working Capital | 81.72 M |
Most of Trevi Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Trevi Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Trevi Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Trevi Therapeutics is extremely important. It helps to project a fair market value of Trevi Stock properly, considering its historical fundamentals such as Working Capital. Since Trevi Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Trevi Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Trevi Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Based on the company's disclosures, Trevi Therapeutics has a Working Capital of 81.72 M. This is 80.8% lower than that of the Pharmaceuticals sector and 84.83% lower than that of the Health Care industry. The working capital for all United States stocks is 94.47% higher than that of the company.
Trevi Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Trevi Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Trevi Therapeutics could also be used in its relative valuation, which is a method of valuing Trevi Therapeutics by comparing valuation metrics of similar companies.Trevi Therapeutics is currently under evaluation in working capital category among its peers.
Trevi Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Trevi Therapeutics from analyzing Trevi Therapeutics' financial statements. These drivers represent accounts that assess Trevi Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Trevi Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 43.7M | 17.9M | 124.6M | 132.7M | 119.4M | 63.2M | |
| Enterprise Value | 12.9M | (4.3M) | 121.2M | 101.6M | 116.9M | 64.4M |
Trevi Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Trevi Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Trevi Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Trevi Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | 303.81 M | ||||
| Shares Outstanding | 89.37 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 70.42 % | ||||
| Number Of Shares Shorted | 4.66 M | ||||
| Price To Book | 6.24 X | ||||
| EBITDA | (33.8 M) | ||||
| Net Income | (29.07 M) | ||||
| Cash And Equivalents | 77.86 M | ||||
| Cash Per Share | 1.82 X | ||||
| Total Debt | 1.34 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 5.18 X | ||||
| Book Value Per Share | 0.78 X | ||||
| Cash Flow From Operations | (31.71 M) | ||||
| Short Ratio | 1.30 X | ||||
| Earnings Per Share | (0.44) X | ||||
| Target Price | 9.81 | ||||
| Number Of Employees | 27 | ||||
| Beta | 1.01 | ||||
| Market Capitalization | 368.19 M |